Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UPJOHN FAILED TO SHOW "POTENTIAL HARM" FROM ANTI-BALDNESS PRODUCTS

Executive Summary

UPJOHN FAILED TO SHOW "POTENTIAL HARM" FROM ANTI-BALDNESS PRODUCTS Helsinki Formula and New Generation, a Las Vegas District Court judge ruled Feb. 10. The decision denies Upjohn's request for a preliminarily injunction against advertising for the two products. In his decision, Judge Lloyd George said that Rogaine topical minoxidil marketer Upjohn could not show the court that its prescription hair growth product would be irreparably injured by ads for the two mail-order anti-baldness treatments. Upjohn had filed suit against Helsinki Formula marketer Pantron I and New Generation marketer California Pacific Research in October in Reno and Las Vegas District Courts, respectively. The validity of the companies hair growth/hair loss preventions was not addressed by the ruling. However, the future of ads for Helsinki Formula and New Generation remains uncertain. The Federal Trade Commission (FTC) is awaiting judges' decisions on its request that ads for the products be preliminarily enjoined for being false and deceptive. The FTC charged in Reno District Court Nov. 14 that California Pacific Research claims that its New Generation product "reduces excessive hair loss" and other hair growth claims were false. A week prior to that, the commission filed similar charges against Pantron I in federal court in Las Vegas. Hearings were held Feb. 13 in the New Generation case and Feb. 22 in the Pantron case. The judges have not yet weighed in with their decisions.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS015183

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel